Nothing about sarcoidosis is easy. First identified in 1877, it is quite common. In the United States, lifetime risk is 2.4% and 0.85% for African American persons and White persons, respectively.

CHICAGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at ...

A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis. In a clinical study, the inhibition of a ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with the JAK inhibitor tofacitinib saw a dose-dependent response in the treatment of cutaneous ...

Sarcoidosis is a multi-systemic disease of unknown etiology with a clinical presentation ranging from asymptomatic disease to organ failure. While some patients with sarcoidosis have spontaneous ...

Please provide your email address to receive an email when new articles are posted on . In a retrospective cohort study, Marc A. Judson, MD, professor of medicine and chief of pulmonary and critical ...

Task force members from the European Respiratory Society evaluated available evidence for treatment of various manifestations of sarcoidosis but said their recommendations were not the last word. As ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for ...

NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases, today announced ...

“With the brepocitinib CS program now moving into Phase 3 alongside the dermatomyositis and non-infectious uveitis programs, Priovant continues to advance our goal of developing brepocitinib as a ...